Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27558773 | 0.80 | MEN1 (0.56) | MAPTMEN1KMT2APIK3CGGAA | |
| SCHEMBL441888 | 0.79 | MAPT (0.59) | MAPTMEN1KMT2AKMOMAP4K4 | |
| SCHEMBL19933569 | 0.79 | MEN1 (0.82) | MAPTMEN1KMT2AKMOMAP4K4 | |
| SCHEMBL31325204 | 0.79 | NPC1 (0.47) | MAPTKMT2APIK3CBPIK3CGLMNA | |
| SCHEMBL11468806 | 0.79 | AURKA (0.59) | MAPTMEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL25002915 | 0.76 | MAPT (0.56) | MAPTMEN1KMT2AKMOMAP4K4 | |
| SCHEMBL9633293 | 0.76 | KDM4E (0.59) | MAPTMEN1KMT2AKMOMAP4K4 | |
| SCHEMBL30885726 | 0.76 | KDM4E (0.59) | MAPTMEN1KMT2AKMOMAP4K4 | |
| SCHEMBL3412705 | 0.76 | KMO (0.66) | MAPTMEN1KMT2AKMOMAP4K4 | |
| SCHEMBL30885864 | 0.76 | KIF11 (0.47) | MEN1KMT2AKMOL3MBTL1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114477223-B | Preparation method and application of sulfhydryl-functionalized SBA molecular sieve | 中国石油化工股份有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-114105167-B | Sulfhydryl functional MCM-41 molecular sieve and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-114477223-A | Preparation method and application of sulfydryl functionalized SBA molecular sieve | 中国石油化工股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114105167-A | Sulfydryl functionalized MCM-41 molecular sieve and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114477223-B | Preparation method and application of sulfhydryl-functionalized SBA molecular sieve | 中国石油化工股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-114105167-B | Sulfhydryl functional MCM-41 molecular sieve and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-114477223-A | Preparation method and application of sulfydryl functionalized SBA molecular sieve | 中国石油化工股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114105167-A | Sulfydryl functionalized MCM-41 molecular sieve and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349840-B1 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030114447-A1 | Small molecule inhibitors of caspases | SUNESIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003024955-A2 | SMALL MOLECULE INHIBITORS OF CASPASES | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | MAPT 2390/4885MEN1 4336/4885KMT2A 1671/4885 |
| US-20030114447-A1 | Small molecule inhibitors of caspases | CASP1, CASP9, CASP2 | MAPT 3039/4885MEN1 3778/4885KMT2A 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.